Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Upstart Holdings Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Upstart Holdings Inc trades at $22.65 (market cap $2.32B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.1× Upstart Holdings Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Upstart Holdings Inc for 39 Days on average.
| TVTX | UPST | |
|---|---|---|
Market Cap | $4.88B | $2.32B |
Volume | 1,668,577 | 3,123,987 |
Sector | Health | Financials |
52-Week High | $67.52 | $52.74 |
52-Week Low | $26.79 | $22.74 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $5.01B | $3.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
UPST trades at $22.74, down 4.25% on the day, with a bearish technical signal and recent earnings misses. Revenue grew to $1.02B in 2025, turning profitable with $53.60M net income, but cash flow from operations remains negative. The stock is trading well below the consensus price target of $38.13, with analysts divided between Buy and Hold ratings.
The outlook is mixed: strong revenue growth and profitability improvements offer upside potential, but persistent cash burn, high debt levels, and sensitivity to credit markets pose significant risks. Investor sentiment is cautious amid recent price declines and sector-wide pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
